Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, peptide-based nanoparticles were successfully used to deliver the CRISPR-Cas9 system into cancer cells, effectively targeting and editing KRAS mutations, suggesting promising therapeutic potential for cancer treatment.

In this rat study, subcutaneous injections of hydrogen peroxide and cumene hydroperoxide appeared to completely prevent chemotherapy-induced hair loss by inducing cell cycle arrest, suggesting a novel approach to help cancer patients maintain their quality of life during treatment.

This study reports that VP-16-213 (etoposide) shows significant therapeutic activity in several cancers including small cell bronchogenic carcinoma and certain leukemias, with hematologic toxicity being the primary side effect.

This study provides evidence that Fernblock® upregulates antioxidant pathways in cultured keratinocytes, potentially protecting against damage from fine pollutant particles.

This review highlights the promise of non-viral gene delivery systems, particularly genosomes, over traditional viral vectors due to enhanced safety and efficiency in therapeutic nucleic acid delivery for genetic diseases like cystic fibrosis and malignancies.

This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.

This study found that the serine protease inhibitor ONO-3403 significantly suppressed tumor growth in mice with induced squamous cell carcinoma without apparent side effects, suggesting its potential for cancer treatment.

This study found that prostaglandin E2 pretreatment may reduce radiotherapy-induced alopecia by enhancing hair follicle self-repair through transient G1 arrest, suggesting a potential preventive treatment.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study found that doxorubicin-induced oxidative stress downregulates FLIPs and phosphorylates EF2, sensitizing prostate cancer cells to TRAIL; antioxidants may reduce doxorubicin's effectiveness, warranting further investigation.

This review detailed the significant progress and challenges in the design and application of PROTACs, a novel class of cancer therapeutics, highlighting their clinical trials, design complexities, and the role of artificial intelligence in improving their efficacy and selectivity for cancer therapy.

In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This study found that using a recombinant adenoassociated virus to induce survivin expression protected normal tissues from radiation damage in mice, reducing side effects compared to controls.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

This study reported that a bioderived melanoidin/tannic acid nanocomplex forms a durable, antioxidant-active coating on hair fibers, providing enhanced UV protection and improving tensile resilience by suppressing oxidative stress and activating endogenous antioxidant pathways.

This study found that the medicinal formula YH0618 may reduce toxicity from the chemotherapy drug doxorubicin, improving side effects like hair loss and organ damage, while maintaining its anti-cancer effects.

This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.

This review discusses the discovery and potential therapeutic uses of proteasome inhibitors across various diseases, including cancer and autoimmune conditions, but does not present new clinical data.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

This study found that normal human melanocytes can be protected from apoptosis through both PI 3-kinase/Akt-dependent and independent pathways, with insulin and TPA offering nearly complete protection.

This article reviews cell proteomic footprinting technology and its application in improving the authentication and quality control of cell-based immunotherapeutics, without providing new clinical results.

This study found that radiation-induced salivary gland dysfunction in mice involves microvascular damage mediated by ceramide and reactive oxygen species, suggesting ROS scavengers could protect salivary function during radiotherapy for head and neck cancer.

In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.

This study found that etoposide enhances the radiosensitivity of CT26 colorectal adenocarcinoma in BALB/c mice, significantly inhibiting tumor growth without significant toxicity.

This article discusses the genetic polymorphisms affecting the antioxidant system and suggests that personalized detoxification plans and nutrition may be beneficial for patients with chronic diseases, but it reports no new clinical findings.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

This review discusses nanoparticle systems for cancer treatment and reports no new clinical results; the authors emphasize their potential to reduce systemic toxicity and call for further development.